Exploring RNA Quality Control in Alzheimer's and Tauopathies: A Discussion with MD Ph.D Zuniga

In this episode, we are joined by MD/Ph.D. Zuniga is at the forefront of research into the intricate mechanisms of Alzheimer's disease and related tauopathies. Alzheimer's patients often exhibit evidence of altered RNA processing. However, the causal link between these changes and neurodegeneration and the mechanics of how such alterations occur remain somewhat elusive.Dr. Zuniga provides insight into these issues through her ground-breaking work using Drosophila melanogaster models of tauopathy. Her team discovered that the activity of nonsense-mediated mRNA decay (NMD), a key RNA quality control mechanism, is reduced in these models. Importantly, the manipulation of the NMD machinery could significantly alter tau-induced neurotoxicity, establishing a causal link between deficits in NMD and neurodegeneration.The team identified the cause of NMD deficits to be aberrant RNA export and RNA accumulation within nuclear envelope invaginations in tauopathy. Significantly, they also identified a pharmacological activator of NMD that suppressed neurodegeneration in tau transgenic Drosophila, suggesting that these RNA quality control deficits can be targeted therapeutically.Join us as Dr. Zuniga guides us through the complexities of her research and its implications for the potential treatment of tauopathies, providing a new perspective on these challenging neurodegenerative disorders.Keywords: Dr. Zuniga, Alzheimer's Disease, Tauopathies, RNA Quality Control, Neurodegeneration, Nonsense-mediated mRNA Decay, Drosophila Melanogaster, Tauopathy, Therapeutics.doi: 10.1002/alz.12653. Our studies suggest that NMD activators should be explored for their potential therapeutic value to patients with tauopathies.